Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50–59 years at increased risk of severe RSV disease and those aged ≥60 years

Background Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality in adults aged 50–59 years at increased risk of severe RSV disease due to specific underlying conditions (i.e. ’50–59 years at-increased-risk [AIR] population’), and in older adults aged ≥60 years (i.e. ‘≥60 y...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Kentaro Tajima, Eleftherios Zarkadoulas, Joost Simons, Daisuke Kurai, Mei Grace, Jonathan Graham, Yufan Ho, Frederik Verelst
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2026-12-01
Serie:	Expert Review of Vaccines
Soggetti:	Adjuvanted RSV prefusion F protein vaccine at-increased-risk comorbidities cost-effectiveness Japan older adults
Accesso online:	https://www.tandfonline.com/doi/10.1080/14760584.2026.2626921
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!